KR100533854B1 - 항-cd6 단일클론항체 및 이를 포함하는 건선치료용 약제조성물 - Google Patents

항-cd6 단일클론항체 및 이를 포함하는 건선치료용 약제조성물 Download PDF

Info

Publication number
KR100533854B1
KR100533854B1 KR1019970704893A KR19970704893A KR100533854B1 KR 100533854 B1 KR100533854 B1 KR 100533854B1 KR 1019970704893 A KR1019970704893 A KR 1019970704893A KR 19970704893 A KR19970704893 A KR 19970704893A KR 100533854 B1 KR100533854 B1 KR 100533854B1
Authority
KR
South Korea
Prior art keywords
ior
cells
psoriasis
treatment
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019970704893A
Other languages
English (en)
Korean (ko)
Other versions
KR19980701502A (ko
Inventor
조세 엔리케 몬테로 카지미로
조세파 롬바르데로 발라다레스
롤란도 페레즈 로드리구에즈
파트리시아 시에라 블라즈퀘즈
블란카 로자 토르모 브라보
Original Assignee
센트로 데 인무노로지아 몰레큘라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센트로 데 인무노로지아 몰레큘라 filed Critical 센트로 데 인무노로지아 몰레큘라
Publication of KR19980701502A publication Critical patent/KR19980701502A/ko
Application granted granted Critical
Publication of KR100533854B1 publication Critical patent/KR100533854B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/205—Scaling palpular diseases, e.g. psoriasis, pytiriasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1019970704893A 1995-11-17 1996-11-18 항-cd6 단일클론항체 및 이를 포함하는 건선치료용 약제조성물 Expired - Lifetime KR100533854B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU1995120A CU22584A1 (es) 1995-11-17 1995-11-17 Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
CUCU120/95 1995-11-17
PCT/CU1996/000004 WO1997019111A2 (es) 1995-11-17 1996-11-18 Anticuerpos monoclonales anti-cd6 y sus utilizaciones

Publications (2)

Publication Number Publication Date
KR19980701502A KR19980701502A (ko) 1998-05-15
KR100533854B1 true KR100533854B1 (ko) 2006-09-20

Family

ID=5459401

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970704893A Expired - Lifetime KR100533854B1 (ko) 1995-11-17 1996-11-18 항-cd6 단일클론항체 및 이를 포함하는 건선치료용 약제조성물

Country Status (15)

Country Link
US (1) US6572857B1 (https=)
EP (1) EP0807125B1 (https=)
JP (1) JP4113929B2 (https=)
KR (1) KR100533854B1 (https=)
CN (1) CN1222540C (https=)
AT (1) ATE280783T1 (https=)
AU (1) AU722882B2 (https=)
BR (1) BRPI9607171B1 (https=)
CA (1) CA2210751C (https=)
CU (1) CU22584A1 (https=)
DE (1) DE69633717T2 (https=)
DK (1) DK0807125T3 (https=)
ES (1) ES2231826T3 (https=)
PT (1) PT807125E (https=)
WO (1) WO1997019111A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1054316A1 (zh) * 2000-05-26 2003-11-28 Smithkline Beecham Corporation 用於治疗rank配体介导疾病的抗-rank配体单克隆抗体
CU23097A1 (es) 2002-10-23 2005-11-18 Centro Inmunologia Molecular Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método
US20070003568A1 (en) 2003-02-24 2007-01-04 Alice Dautry-Varsat Secreted chlamydia polypeptides, polynucleotides coding therefor, therapeutic and diagnostic uses thereof
KR101482956B1 (ko) * 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 류마티스 관절염의 진단 및 치료에 사용되는 항-ｃｄ6 단일클론성 항체를 포함하는 약학 조성물
KR101482959B1 (ko) 2006-12-26 2015-01-15 센트로 데 인뮤놀러지아 모레큘러 Ｂ-세포 만성 림프구성 백혈병의 진단 및 치료에 유용한 종양 세포에서 세포사멸을 유도할 수 있는 약학 조성물
CA2711394A1 (en) 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
WO2009113083A1 (en) * 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
RS57215B1 (sr) * 2010-07-15 2018-07-31 Adheron Therapeutics Inc Humanizovana antitela koja ciljaju ec1 domen kadherina-11 i kompozicije i postupci koji su u vezi sa njima
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
BR112013033988B1 (pt) 2011-07-01 2021-10-19 Beckman Coulter, Inc. Métodos de identificação e isolamento de uma ou mais populações de células t regulatórias imunossupressoras
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
FR3000216B1 (fr) * 2012-12-21 2015-02-06 Galderma Res & Dev Utilisation de proteases particulieres pour la detection de trichophytons et de pathologies associees
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3024485B1 (en) 2013-07-23 2020-11-18 Biocon Limited Use of a cd6 binding partner and method based thereon
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN105504062B (zh) * 2015-12-25 2019-06-04 百泰生物药业有限公司 一种抗CD6单抗T1h的检测性抗体及应用
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
CN112424226B (zh) * 2018-02-27 2025-03-14 平衡生物科技股份有限公司 用于治疗重度哮喘的抗cd6抗体
US12281151B2 (en) 2018-06-29 2025-04-22 City Of Hope CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
BR112021016967A2 (pt) 2019-02-26 2021-11-23 Equillium Inc Composições de anticorpo anti-cd6 e métodos para tratar lúpus
WO2021138454A1 (en) 2019-12-30 2021-07-08 City Of Hope Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
CA3231281A1 (en) 2021-09-08 2023-03-16 Yanelda De Los Angeles Garcia Vega Use of anti-cd6 monoclonal antibodies in the prevention of cellular and organ damage resulting from hyper-inflammatory response
WO2025096685A1 (en) 2023-10-30 2025-05-08 City Of Hope Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers
CN120005027B (zh) * 2025-04-10 2025-09-23 中国水产科学研究院长江水产研究所 大口黑鲈cd6抗原结合肽、及其单克隆抗体和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012614A1 (en) * 1993-11-02 1995-05-11 Duke University Cd6 ligand
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Clin. Immunol. Immunopathol., Vol.64(3), pp. 248-253 (1992. 12. 31.) *
Immunotechnology, Vol.1, pp. 107-113 (1995. 8. 31.) *

Also Published As

Publication number Publication date
BRPI9607171B1 (pt) 2016-07-19
CU22584A1 (es) 1999-11-03
CN1222540C (zh) 2005-10-12
AU7690596A (en) 1997-06-11
DE69633717D1 (de) 2004-12-02
WO1997019111A2 (es) 1997-05-29
ES2231826T3 (es) 2005-05-16
BR9607171A (pt) 1997-11-11
JPH11506017A (ja) 1999-06-02
EP0807125B1 (en) 2004-10-27
WO1997019111A3 (es) 1998-02-12
PT807125E (pt) 2005-03-31
CA2210751A1 (en) 1997-05-29
KR19980701502A (ko) 1998-05-15
DE69633717T2 (de) 2006-02-02
DK0807125T3 (da) 2005-03-14
EP0807125A2 (en) 1997-11-19
ATE280783T1 (de) 2004-11-15
JP4113929B2 (ja) 2008-07-09
MX9705445A (es) 1998-06-30
CA2210751C (en) 2007-01-30
CN1175957A (zh) 1998-03-11
US6572857B1 (en) 2003-06-03
AU722882B2 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
KR100533854B1 (ko) 항-cd6 단일클론항체 및 이를 포함하는 건선치료용 약제조성물
US6180377B1 (en) Humanized antibodies
CA2623109C (en) Nk cell-depleting antibodies for treating immunoproliferative disorders
JP4157160B2 (ja) 改変抗体可変領域の調製のための方法
DE3853636T3 (de) Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
JP3383795B2 (ja) ＴＮＦ−αに特異的なキメラ抗体分子
WO1997019111A9 (es) Anticuerpos monoclonales anti-cd6 y sus utilizaciones
EP0807125A1 (en) Monoclonal antibodies anti-cd6 and their uses
HU230197B1 (hu) Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
JPH08502246A (ja) Ｔ細胞抗原レセプターの画定された領域と反応性のモノクローナル抗体
MXPA98000760A (en) Methods for the treatment of asthma allergy
ES2307301T3 (es) ANTICUERPO LO-CD2a Y USOS DEL MISMO PARA INHIBIR LA ACTIVACION Y PROLIFERACION DE CELULAS T.
JPH05310596A (ja) 抗体を含有する免疫抑制剤
JP2024069463A (ja) デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体
DE69029858T2 (de) Behandlung von einer autoimmun-krankheit
CN113166239A (zh) 抗il-17a抗体及其应用
KR101266389B1 (ko) 항 인간 테나신 단클론 항체
TW201206476A (en) Pharmaceutical composition for treating rheumatoid arthritis with anti-IL-19 antibody
AU719369B2 (en) Monoclonal antiidiotypic antibodies (AB2) and their uses
US20220153845A1 (en) A method for immunosuppression
JP2001521374A (ja) Ｔ細胞活性化および増殖を阻害するＬＯ―ＣＤ２ａ抗体およびその用途
AU2012202895A1 (en) Compositions and methods for treating proliferative disorders
Couser et al. Summary report: National Institutes of Health conference on monoclonal antibodies in renal research
HK40057229A (en) Anti-il-17a antibody and use thereof
Natali et al. Human Ia-like antigens: Analysis of the tissue distribution and immunochemical profile with monoclonal antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19970718

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20011119

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040518

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20050329

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20050923

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20051130

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20051130

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20081128

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20091201

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20101129

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20111125

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20121015

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20121015

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20131007

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20131007

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20140922

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20140922

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20150821

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20150821

Start annual number: 11

End annual number: 11

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20170518

Termination category: Expiration of duration